U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24O6
Molecular Weight 360.401
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIPTOLIDE

SMILES

[H][C@@]12C[C@@H]3O[C@@]34[C@H](O)[C@]5(O[C@H]5[C@@H]6O[C@]46[C@@]1(C)CCC7=C2COC7=O)C(C)C

InChI

InChIKey=DFBIRQPKNDILPW-CIVMWXNOSA-N
InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1

HIDE SMILES / InChI
Triptolide, the active component of Tripterygium wilfordii Hook F has been used to treat autoimmune and inflammatory conditions for over two hundred years in traditional Chinese medicine. Triptolide possesses immunosuppressive, anti-inflammatory, and anti-cancer effects. Triptolide is a woody vine which is widely distributed in Eastern and Southern China. In China, triptolide is frequently used to treat autoimmune and/or inflammatory diseases due to its favorable cost–benefit ratio. Commercial preparations of triptolide have been commonly used for the treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, nephritis and psoriasis.Triptolide has been demonstrated to exert novel chondroprotective and anti-inflammatory effects on rheumatoid arthritis. Triptolide has been used to treat ADPKD patients in clinical trials in China. Triptolide significantly protected glomerular filtration rate (eGFR) of ADPKD patients compared with placebo. Two recent small clinical studies have demonstrated tiptolide’s effectiveness against rheumatoid arthritis. A larger study confirmed the therapeutic effects of triptolide in the aforementioned studies. Triptolide is among the most powerful and broadly active antiinflammatory/immunomodulating natural products ever discovered. Triptolide acts at nanomolar concentrations and inhibits the production of various cellular targets including inflammatory cytokines, cyclooxygenase, inducible nitric oxide synthase and metalloproteinases and transcription factors. The anti-tumor activity of Triptolide in vitro and in various tumor-bearing animal models has been investigated for years, and many findings showed that Triptolide is a promising agent in anti-tumor therapy. Triptolide has been approved for Phase I clinical trials for the treatment of prostate cancer, but the anti-tumor effect and mechanism of TPL need to be further elucidated.

CNS Activity

Curator's Comment: Triptolide crosses the blood-brain barrier easily due to its small molecular size and lipophilic property. Triptolide inhibits amyloid-β production and protects neural cells by inhibiting CXCR2 activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
14.18 µM [IC50]
8.36 µM [IC50]
Target ID: HuCCT1, human cholangiocarcinoma
12.6 nM [IC50]
30.0 pM [IC50]
14.0 nM [IC50]
Conditions
OverviewDrug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis.
2001 Mar
Caspase 3 is involved in the apoptosis induced by triptolide in HK-2 cells.
2009 Jun
Heat shock protein 72 protects kidney proximal tubule cells from injury induced by triptolide by means of activation of the MEK/ERK pathway.
2009 May-Jun
Sex differences in subacute toxicity and hepatic microsomal metabolism of triptolide in rats.
2010 Apr 30
Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity.
2011 Aug 10
Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo.
2013
Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer.
2014 Jul
Triptolide disrupts fatty acids and peroxisome proliferator-activated receptor (PPAR) levels in male mice testes followed by testicular injury: A GC-MS based metabolomics study.
2015 Oct 2
Patents

Sample Use Guides

Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28)
Route of Administration: Intravenous
The A549/Taxol cells were treated with different concentrations of Triptolide (0.03, 0.3 or 3 uM/l) for 2, 4, 6 and 12 h. On exposure to 3 uM Triptolide for 2, 4, 6 and 12 h, the extent of cell apoptosis observed markedly increased. The inhibitory effect reached a maximum with 3 uM Triptolide at the 12 h time point (cell apoptotic rate, 65.33%), whereas the apoptotic rate of the control group was 7.23% at 12 h.
Name Type Language
TRIPTOLIDE
MI   WHO-DD  
Common Name English
(3BS,4AS,5AS,6R,6AR,7AS,7BS,8AS,8BS)-3B,4,4A,6,6A,7A,7B,8B,9,10-DECAHYDRO-6-HYDROXY-8B-METHYL-6A-(1-METHYLETHYL)TRISOXIRENO(4B,5:6,7:8A,9)PHENANTHRO(1,2-C)FURAN-1(3H)-ONE
Common Name English
(3BS,4AS,5AS,6R,6AR,7AS,7BS,8AS,8BS)-3B,4,4A,6,6A,7A,7B,8B,9,10-DECAHYDRO-6-HYDROXY-6A-ISOPROPYL-8B-METHYLTRISOXIRENO(6,7:8A,9:4B,5)PHENANTHRO(1,2-C)FURAN-1(3H)-ONE
Common Name English
NSC-163062
Code English
TRIPTOLIDE [MI]
Common Name English
Triptolide [WHO-DD]
Common Name English
Code System Code Type Description
ALANWOOD
triptolide
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
MESH
C001899
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
SMS_ID
100000128444
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID5041144
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
WIKIPEDIA
Triptolide
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
NSC
163062
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
PUBCHEM
107985
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
FDA UNII
19ALD1S53J
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
DRUG BANK
DB12025
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
MERCK INDEX
m11193
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY Merck Index
CAS
38748-32-2
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY
EVMPD
SUB35481
Created by admin on Fri Dec 15 19:01:53 GMT 2023 , Edited by admin on Fri Dec 15 19:01:53 GMT 2023
PRIMARY